Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis C

Free Subscription Articles published in Hepatology Retrieve available abstracts of 38 articles: HTML format

Single Articles

September 2025
1. SANDULESCU O, Dudman SG, Gmizic I, Garcia F, et al
   Global Hepatitis C elimination: Updates, challenges, and opportunities from real-world experiences in Europe and North America.
   Hepatology. 2025 Sep 26. doi: 10.1097/HEP.0000000000001548.
   PubMed    
   
   
   
2. GOMEZ-ESCOBAR E, Flores N, Shoukry NH
   One step closer to a pan-genotypic hepatitis C vaccine.
   Hepatology. 2025 Sep 17. doi: 10.1097/HEP.0000000000001530.
   PubMed    
   
   
   June 2025
3. MACHIDA K, Tsukamoto H, Liu JC, Han YP, et al
   Retraction: C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
   Hepatology. 2025;81:E181.
   PubMed    
   
   
   February 2025
4. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
   Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
   Hepatology. 2025;81:609-624.
   PubMed     Abstract available
   
   
   January 2025
5. YOUNOSSI ZM, de Avila L, Racila A, Nader F, et al
   Prevalence and predictors of cirrhosis and portal hypertension in the united states.
   Hepatology. 2025 Jan 29. doi: 10.1097/HEP.0000000000001243.
   PubMed     Abstract available
   
   
   
6. PATEL K, Asrani SK, Fiel MI, Levine D, et al
   Accuracy of blood-based biomarkers for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline.
   Hepatology. 2025;81:358-379.
   PubMed     Abstract available
   
   
   November 2024
7. 
   Erratum: JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in the evaluation of virus neutralization.
   Hepatology. 2024;80:E86.
   PubMed    
   
   
   October 2024
8. COLPITTS CC, Baumert TF
   Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions.
   Hepatology. 2024 Oct 22. doi: 10.1097/HEP.0000000000001132.
   PubMed    
   
   
   
9. OLESEN CH, Collignon L, Velazquez-Moctezuma R, Fanalista M, et al
   Prevalence of hepatitis C virus hypervariable region 1 insertions and their role in antibody evasion.
   Hepatology. 2024 Oct 8. doi: 10.1097/HEP.0000000000001114.
   PubMed     Abstract available
   
   
   August 2024
10. VAN DER MEER AJ, Sonneveld MJ
    Towards risk-based surveillance for hepatocellular carcinoma after HCV cure?
    Hepatology. 2024 Aug 13. doi: 10.1097/HEP.0000000000001057.
    PubMed    
    
    
    
11. STAFYLIS C, Vij AP, Klausner JD
    Letter to the editor: Bridging the gap between hepatitis C virus diagnosis and treatment to achieve elimination in the united states.
    Hepatology. 2024 Aug 8. doi: 10.1097/HEP.0000000000001051.
    PubMed    
    
    
    July 2024
12. SEMMLER G, Alonso Lopez S, Pons M, Lens S, et al
    Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.
    Hepatology. 2024 Jul 8. doi: 10.1097/HEP.0000000000001005.
    PubMed     Abstract available
    
    
    
13. 
    Erratum: c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
    Hepatology. 2024;80:E21.
    PubMed    
    
    
    June 2024
14. LAW JL, Drummer HE
    Bridging the gap: A new tool to down select HCV vaccine candidates.
    Hepatology. 2024 Jun 27. doi: 10.1097/HEP.0000000000000948.
    PubMed    
    
    
    
15. BERENGUER J, Bellon JM, Banares R, Gonzalez-Garcia J, et al
    Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 20. doi: 10.1097/HEP.0000000000000977.
    PubMed    
    
    
    
16. HUANG L, Zou L
    Letter to the Editor: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis.
    Hepatology. 2024 Jun 17. doi: 10.1097/HEP.0000000000000974.
    PubMed    
    
    
    
17. CORNBERG M, Wedemeyer H
    Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination!
    Hepatology. 2024 Jun 5. doi: 10.1097/HEP.0000000000000958.
    PubMed    
    
    
    May 2024
18. POL S, Thompson AJ, Collins M, Venier E, et al
    Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study.
    Hepatology. 2024 May 20. doi: 10.1097/HEP.0000000000000923.
    PubMed     Abstract available
    
    
    
19. LO RE V 3RD, Price JC, Schmitt S, Terrault N, et al
    The obstacle is the way: Finding a path to hepatitis C elimination.
    Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807.
    PubMed    
    
    
    
20. HALL EW, Bradley H, Barker LK, Lewis K, et al
    Estimating hepatitis C prevalence in the United States, 2017-2020.
    Hepatology. 2024 May 13. doi: 10.1097/HEP.0000000000000927.
    PubMed     Abstract available
    
    
    
21. SEMMLER G, Mandorfer M
    The fade-out of HCV coinfection of people who live with HIV.
    Hepatology. 2024 May 1. doi: 10.1097/HEP.0000000000000922.
    PubMed    
    
    
    April 2024
22. COLLIGNON L, Holmbeck K, Just A, Verhoye L, et al
    JFH1-based Core-NS2 genotype variants of HCV with genetic stability in vivo and in vitro: Important tools in evaluation of virus neutralization.
    Hepatology. 2024 Apr 23. doi: 10.1097/HEP.0000000000000897.
    PubMed     Abstract available
    
    
    March 2024
23. TIAN F, Forouzannia F, Feng Z, Biondi MJ, et al
    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries.
    Hepatology. 2024 Mar 13. doi: 10.1097/HEP.0000000000000779.
    PubMed     Abstract available
    
    
    
24. BERENGUER J, Aldamiz-Echevarria T, Hontanon V, Fanciulli C, et al
    Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV coinfected patients with advanced Fibrosis/Cirrhosis.
    Hepatology. 2024 Mar 7. doi: 10.1097/HEP.0000000000000838.
    PubMed     Abstract available
    
    
    
25. KONDILI LA, Craxi A
    Hepatitis C elimination: Tailoring the approach to each country's needs and realities.
    Hepatology. 2024 Mar 5. doi: 10.1097/HEP.0000000000000824.
    PubMed    
    
    
    February 2024
26. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed     Abstract available
    
    
    
27. MOCTEZUMA-VELAZQUEZ C, Wong YJ, Montano-Loza AJ
    Editorial: Promise and pitfalls of a natural killer cell signature for hepatocellular carcinoma detection in HCV patients with sustained virological response.
    Hepatology. 2024 Feb 14. doi: 10.1097/HEP.0000000000000797.
    PubMed    
    
    
    
28. YU H, Shin EC
    Duet of humoral and cellular immunity for conquering hepatitis C virus.
    Hepatology. 2024 Feb 9. doi: 10.1097/HEP.0000000000000769.
    PubMed    
    
    
    January 2024
29. GRIDLEY J, Holland B, Salinas E, Trivedi S, et al
    Concerted synergy between viral-specific IgG and CD8+ T cells is critical for clearance of an HCV-related rodent hepacivirus.
    Hepatology. 2024 Jan 12. doi: 10.1097/HEP.0000000000000753.
    PubMed     Abstract available
    
    
    
30. BROWN AJ, Won JJ, Wolfisberg R, Fahnoe U, et al
    Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice.
    Hepatology. 2024;79:183-197.
    PubMed     Abstract available
    
    
    November 2023
31. LEE J, Gil D, Park H, Lee Y, et al
    A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression.
    Hepatology. 2023 Nov 17. doi: 10.1097/HEP.0000000000000683.
    PubMed     Abstract available
    
    
    July 2023
32. MUFTAH AA, Banala C, Raasikh T, Jamali T, et al
    Telehealth interventions in patients with chronic liver diseases: A systematic review.
    Hepatology. 2023;78:179-194.
    PubMed     Abstract available
    
    
    June 2023
33. GOMER A, Klohn M, Jagst M, Nocke M, et al
    Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients.
    Hepatology. 2023 Jun 20. doi: 10.1097/HEP.0000000000000514.
    PubMed     Abstract available
    
    
    
34. GOUTTENOIRE J, Neyts J
    Towards antivirals against hepatitis E: In the steps of hepatitis C.
    Hepatology. 2023 Jun 12. doi: 10.1097/HEP.0000000000000509.
    PubMed    
    
    
    May 2023
35. TERRAULT N, Torres H, Price J, Bhattacharya D, et al
    The national hepatitis c elimination program - AASLD's coalition and call to action.
    Hepatology. 2023 May 12. doi: 10.1097/HEP.0000000000000444.
    PubMed    
    
    
    April 2023
36. DIETZ J, Lohmann V
    Therapeutic preparedness: DAA resistant Hepatitis C virus variants in vitro and in vivo.
    Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000405.
    PubMed    
    
    
    
37. FERNANDEZ-ANTUNEZ C, Wang K, Fahnoe U, Mikkelsen LS, et al
    Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000353.
    PubMed     Abstract available
    
    
    
38. VO-QUANG E, Soulier A, Ndebi M, Rodriguez C, et al
    Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000379.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.